Relay Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Relay Therapeutics, Inc. (RLAY) reported Other Comprehensive Income (Loss), Net of Tax of -$1.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- Relay Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$1.38M.
- Relay Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$172.00K, a 116.72% decline year-over-year.
- Relay Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $240.00K.
- Relay Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $656.00K, a 82.96% decline year-over-year.
- Relay Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $1.72M.
- Relay Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was -$795.00K, a 107.78% decline from fiscal 2023.
- Relay Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $10.22M.
- Relay Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$9.33M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.38M 10-Q · filed 2026-08-06 | -$2.29M 10-Q · filed 2026-08-06 | -$1.31M derived: sum of 3 quarters · filed 2026-08-06 | -$657.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$172.00K 10-Q · filed 2026-05-05 | $68.00K derived: sum of 2 quarters · filed 2026-05-05 | $724.00K derived: sum of 3 quarters · filed 2026-05-05 | $523.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $896.00K derived: sum of 2 quarters · filed 2026-02-26 | $695.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.72M 10-K · filed 2026-02-26 |
| 2025-09-30 | $656.00K 10-Q · filed 2025-11-06 | $455.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.48M 10-Q · filed 2025-11-06 | -$2.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$201.00K 10-Q · filed 2026-08-06 | $828.00K 10-Q · filed 2026-08-06 | -$2.67M derived: sum of 3 quarters · filed 2026-08-06 | $1.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.03M 10-Q · filed 2026-05-05 | -$2.47M derived: sum of 2 quarters · filed 2026-05-05 | $1.38M derived: sum of 3 quarters · filed 2026-05-05 | $1.20M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $349.00K derived: sum of 2 quarters · filed 2026-02-26 | $167.00K derived: sum of 3 quarters · filed 2026-02-26 | -$795.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.85M 10-Q · filed 2025-11-06 | $3.67M derived: sum of 2 quarters · filed 2025-11-06 | $2.71M 10-Q · filed 2025-11-06 | $5.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$182.00K 10-Q · filed 2025-08-07 | -$1.14M 10-Q · filed 2025-08-07 | $2.05M derived: sum of 3 quarters · filed 2026-02-26 | $4.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$962.00K 10-Q · filed 2025-05-05 | $2.23M derived: sum of 2 quarters · filed 2026-02-26 | $4.92M derived: sum of 3 quarters · filed 2026-02-26 | $4.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.88M derived: sum of 2 quarters · filed 2026-02-26 | $5.61M derived: sum of 3 quarters · filed 2026-02-26 | $10.22M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.69M 10-Q · filed 2024-11-06 | $2.42M derived: sum of 2 quarters · filed 2024-11-06 | $7.03M 10-Q · filed 2024-11-06 | $10.00M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$279.00K 10-Q · filed 2024-08-06 | $4.34M 10-Q · filed 2024-08-06 | $7.31M derived: sum of 3 quarters · filed 2025-02-26 | $5.83M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $4.62M 10-Q · filed 2024-05-02 | $7.59M derived: sum of 2 quarters · filed 2025-02-26 | $6.10M derived: sum of 3 quarters · filed 2025-02-26 | $3.42M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.49M derived: sum of 2 quarters · filed 2025-02-26 | -$1.20M derived: sum of 3 quarters · filed 2025-02-26 | -$9.33M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$1.48M 10-Q · filed 2023-11-02 | -$4.17M derived: sum of 2 quarters · filed 2023-11-02 | -$12.30M 10-Q · filed 2023-11-02 | -$13.40M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$2.69M 10-Q · filed 2023-08-08 | -$10.82M 10-Q · filed 2023-08-08 | -$11.92M derived: sum of 3 quarters · filed 2024-02-22 | -$11.84M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$8.13M 10-Q · filed 2023-05-04 | -$9.23M derived: sum of 2 quarters · filed 2024-02-22 | -$9.15M derived: sum of 3 quarters · filed 2024-02-22 | -$9.23M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$1.02M derived: sum of 2 quarters · filed 2024-02-22 | -$1.10M derived: sum of 3 quarters · filed 2024-02-22 | -$1.15M 10-K · filed 2024-02-22 |
| 2021-09-30 | $74.00K 10-Q · filed 2022-11-03 | -$2.00K derived: sum of 2 quarters · filed 2022-11-03 | -$54.00K 10-Q · filed 2022-11-03 | -$166.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$76.00K 10-Q · filed 2022-08-04 | -$128.00K 10-Q · filed 2022-08-04 | -$240.00K derived: sum of 3 quarters · filed 2023-02-23 | -$695.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$52.00K 10-Q · filed 2022-05-05 | -$164.00K derived: sum of 2 quarters · filed 2023-02-23 | -$619.00K derived: sum of 3 quarters · filed 2023-02-23 | -$1.38M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$567.00K derived: sum of 2 quarters · filed 2023-02-23 | -$1.33M derived: sum of 3 quarters · filed 2023-02-23 | -$261.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | -$455.00K 10-Q · filed 2021-11-10 | -$1.22M derived: sum of 2 quarters · filed 2021-11-10 | -$149.00K 10-Q · filed 2021-11-10 | -$231.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$763.00K 10-Q · filed 2021-08-12 | $306.00K 10-Q · filed 2021-08-12 | $224.00K derived: sum of 3 quarters · filed 2022-02-24 | $156.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $1.07M 10-Q · filed 2021-05-13 | $987.00K derived: sum of 2 quarters · filed 2022-02-24 | $919.00K derived: sum of 3 quarters · filed 2022-02-24 | $1.39M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$150.00K derived: sum of 2 quarters · filed 2022-02-24 | $325.00K derived: sum of 3 quarters · filed 2022-02-24 | $325.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | -$68.00K 10-Q · filed 2020-11-12 | $407.00K derived: sum of 2 quarters · filed 2020-11-12 | $407.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $475.00K 10-Q · filed 2020-08-27 | $475.00K 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |